NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Nov 16 2022

· Issued by NATCO Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

NATCO Pharma Limited has issued a press release regarding a legal update on its marketing partner's appeal in the US. The Appeals Court has rejected Alvogen's appeal concerning Ibrutinib Tablets, which are proposed generic equivalents to Imbruvica® Tablets. NATCO and Alvogen are currently evaluating their options moving forward after this decision.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

NATCO Pharma Limited on 6ix

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases